Dec 30, 2025 • Stock Traders Daily
SOMEWHAT-BULLISH
Responsive Playbooks and the BIO Inflection
This article provides an AI-driven analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting a neutral near-term sentiment and a mid-channel oscillation pattern. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis and an exceptional risk-reward setup targeting a 16.4% gain.
Dec 19, 2025 • Stock Traders Daily
SOMEWHAT-BEARISH
Liquidity Mapping Around (BIO) Price Events
The article provides a detailed liquidity mapping analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It outlines institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for potential price movements. The analysis identifies key support and resistance levels and suggests a highly favorable risk-reward setup.
Nov 16, 2025 • Stock Traders Daily
BEARISH
Avoiding Lag: Real-Time Signals in (BIO) Movement
Bio-rad Laboratories Inc. Class A (NYSE: BIO) is showing strong near-term sentiment that could challenge persistent mid and long-term weakness. The article highlights an exceptional 56.8:1 risk-reward short setup targeting a 16.3% downside versus a 0.3% risk. AI models have generated distinct trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Nov 10, 2025 • Sahm
NEUTRAL
Bio-Rad Laboratories (BIO): Assessing Valuation Following Q3 Loss and Share Buyback Completion
Bio-Rad Laboratories (BIO) reported a Q3 net loss and completed a share buyback, leading to an 11.9% share price rebound recently despite long-term underperformance. The company is considered 5.1% undervalued with a fair value of $324, driven by expanded molecular diagnostics platforms and strategic acquisitions. However, this optimism is tempered by persistent instrument demand weakness and margin pressures.
Oct 25, 2025 • Sahm
SOMEWHAT-BULLISH
Bio-Rad Laboratories (BIO): Evaluating Valuation After Major Oncology Diagnostics Partnership Expansion with Biodesix
Bio-Rad Laboratories and Biodesix are expanding their partnership to develop new in vitro diagnostic assays for oncology, leveraging Bio-Rad's Droplet Digital PCR technology. While the stock has seen a recent surge, its five-year returns remain negative, prompting questions about its current valuation. Analysts present differing fair value assessments, with some suggesting overvaluation while a Discounted Cash Flow model indicates significant undervaluation.
Oct 22, 2025 • Quiver Quantitative
BULLISH
Biodesix Expands Partnership with Bio-Rad for Development of Advanced Cancer Diagnostics Using ddPCR Technology
Biodesix has expanded its partnership with Bio-Rad to develop and validate in vitro diagnostic assays for sensitive genomic marker detection in oncology, utilizing Bio-Rad's Droplet Digital™ PCR technology. The initial focus will be on the ddPLEX ESR1 Mutation Detection Assay, crucial for advanced breast cancer treatment. Once validated, Biodesix will offer the assay through its accredited laboratory and seek CMS reimbursement, expanding its personalized medicine offerings.